These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 12630543

  • 1. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
    Pang JT, Fort S, Della Siega A, Cohen EA.
    J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543
    [Abstract] [Full Text] [Related]

  • 2. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM.
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [Abstract] [Full Text] [Related]

  • 3. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL, Topol EJ.
    JAMA; 2000 Sep 27; 284(12):1549-58. PubMed ID: 11000650
    [Abstract] [Full Text] [Related]

  • 4. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P, NICE-3 Investigators.
    Am Heart J; 2003 Oct 27; 146(4):628-34. PubMed ID: 14564315
    [Abstract] [Full Text] [Related]

  • 5. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Casterella PJ, Revenaugh JR, Burke JL, Pearson RR, Bair TL, May HT, Horne B, Anderson JL, Muhlestein JB.
    J Invasive Cardiol; 2008 Mar 27; 20(3):94-8. PubMed ID: 18316822
    [Abstract] [Full Text] [Related]

  • 6. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I.
    Cochrane Database Syst Rev; 2014 Mar 08; (3):CD005208. PubMed ID: 24609741
    [Abstract] [Full Text] [Related]

  • 7. IIb's are not IIb's.
    Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM.
    Am J Cardiol; 2000 Apr 27; 85(8A):23C-31C. PubMed ID: 10793177
    [Abstract] [Full Text] [Related]

  • 8. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
    Brown DL, Fann CS, Chang CJ.
    Am J Cardiol; 2001 Mar 01; 87(5):537-41. PubMed ID: 11230835
    [Abstract] [Full Text] [Related]

  • 9. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 10. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
    Kimmelstiel C, Phang R, Rehman A, Rand W, Miele R, Rhofiry J, MacIsaac DA, Gouveia W, Denier D, Becker RC.
    J Thromb Thrombolysis; 2001 May 17; 11(3):203-9. PubMed ID: 11577258
    [Abstract] [Full Text] [Related]

  • 11. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Am Heart J; 1998 Apr 17; 135(4):S43-55. PubMed ID: 9539495
    [Abstract] [Full Text] [Related]

  • 12. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML.
    Circulation; 1999 Nov 16; 100(20):2045-8. PubMed ID: 10562258
    [Abstract] [Full Text] [Related]

  • 13. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM, Califf RM, Topol EJ.
    J Am Coll Cardiol; 2000 Apr 16; 35(5):1103-15. PubMed ID: 10758948
    [Abstract] [Full Text] [Related]

  • 14. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
    Juran NB.
    Am Heart J; 1999 Oct 16; 138(4 Pt 2):297-306. PubMed ID: 10502235
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
    Cheng JW.
    Am J Health Syst Pharm; 2002 Nov 01; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE, Gupta R, Rajendran S, Luu J, French JK, Juergens CP.
    Cardiovasc Ther; 2016 Oct 01; 34(5):330-6. PubMed ID: 27327862
    [Abstract] [Full Text] [Related]

  • 17. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.
    Circ Cardiovasc Interv; 2009 Jun 01; 2(3):230-6. PubMed ID: 20031720
    [Abstract] [Full Text] [Related]

  • 18. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
    Lincoff AM.
    Am J Cardiol; 1998 Oct 22; 82(8B):36P-42P. PubMed ID: 9809890
    [Abstract] [Full Text] [Related]

  • 19. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G.
    J Thromb Thrombolysis; 2001 Apr 22; 11(2):99-110. PubMed ID: 11406724
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.